CEO Presents at the 6th Annual Cell & Gene Partnering Forum on the Mesa 2016
CEO Presents at Cell & Gene Therapy Investor Day March 2016
Pro-Active Investors : ReNeuron making good progress in clinical trials, says CFO
CEO presents at the 2015 Stem Cell meeting on the MESA
Long term data from first clinical trial of ReNeuron’s stem cell therapy for stroke to be presented at leading stroke conference
Guildford, UK, 17 April 2015: Long term data continue to show good safety profile and evidence of sustained improvements in neurological status and limb function.
BBC Radio 5 Live Interview with Frank Marsh – 31st December 2013
Media Coverage of interim data from clinical trial of ReNeuron’s stem cell therapy for stroke – 27th May 2013
Further data from first clinical trial of ReNeuron’s stem cell therapy for stroke to be presented at leading stroke conference
Guildford, UK, 7 May 2014: ReNeuron Group plc (the “Company”) (AIM: RENE.L) today provides a further update on the PISCES Phase I clinical trial of its ReN001 stem cell therapy for disabled stroke patients ahead of the commencement of a Phase II efficacy study for which patient enrolment has now opened.
Further data from first clinical trial of ReNeuron’s stem cell therapy for stroke to be presented at leading stroke conference
Guildford, UK, 7 May 2014: ReNeuron Group plc (the “Company”) (AIM: RENE.L) today provides a further update on the PISCES Phase I clinical trial of its ReN001 stem cell therapy for disabled stroke patients ahead of the commencement of a Phase II efficacy study for which patient enrolment has now opened.